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RFT1 deficiency in three novel CDG patients
Abstract
The medical significance of N-glycosylation is underlined by a group of inherited human disorders
called Congenital Disorders of Glycosylation (CDG). One key step in the biosynthesis of the
Glc(3)Man(9)GlcNAc(2)-PP-dolichol precursor, essential for N-glycosylation, is the translocation of
Man(5)GlcNAc(2)-PP-dolichol across the endoplasmic reticulum membrane. This step is facilitated by
the RFT1 protein. Recently, the first RFT1-deficient CDG (RFT1-CDG) patient was identified and
presented a severe N-glycosylation disorder. In the present study, we describe three novel CDG patients
with an RFT1 deficiency. The first patient was homozygous for the earlier reported RFT1 missense
mutation (c.199C>T; p.R67C), whereas the two other patients were homozygous for the missense
mutation c.454A>G (p.K152E) and c.892G>A (p.E298 K), respectively. The pathogenic character of the
novel mutations was illustrated by the accumulation of Man(5)GlcNAc(2)-PP-dolichol and by reduced
recombinant DNase 1 secretion. Both the glycosylation pattern and recombinant DNase 1 secretion
could be normalized by expression of normal RFT1 cDNA in the patients' fibroblasts. The clinical
phenotype of these patients comprised typical CDG symptoms in addition to sensorineural deafness,
rarely reported in CDG patients. The identification of additional RFT1-deficient patients allowed to
delineate the main clinical picture of RFT1-CDG and confirmed the crucial role of RFT1 in
Man(5)GlcNAc(2)-PP-dolichol translocation.
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ABSTRACT 
N-glycosylation is an essential form of protein modification, whose medical significance 
is underlined by the group of inherited human disorders called Congenital Disorders of 
Glycosylation (CDG). A key step in the N-glycosylation pathway, the translocation of 
Man5GlcNAc2-PP-dolichol across the endoplasmic reticulum membrane, is catalyzed by 
the RFT1 protein and the first RFT1-deficient CDG patient was recently identified by 
Haeuptle and co-workers. 
In the present study, we describe three novel CDG patients with an RFT1 deficiency. The 
first patient was found to be homozygous for the earlier reported missense mutation 
c.199C>T (p.R67C), while two new point mutations were identified in the other two 
patients. One was homozygous for the missense mutation c.454A>G (p.E152K), while 
the other was homozygous for a G to A transition at nucleotide position 892 (c. 892G>A; 
p.K298E). In the patients’ cells, the pathogenic character of these new mutations was 
illustrated by the typical accumulation of the LLO intermediate Man5GlcNAc2-PP-
dolichol and by reduced recombinant DNase 1 secretion. Both the LLO profile and 
recombinant DNase 1 secretion could be normalized by expression of normal RFT1 
cDNA in the patients’ fibroblasts. Due to the identification of these three additional 
patients, the clinical phenotype of RFT1 deficiency could be further delineated and 
comprises severe mental retardation, failure to thrive, hypotonia, epilepsy, myoclonic 
jerks, decreased visual acuity, sensorineural deafness and feeding problems. 
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Introduction 
N-glycosylation is a post-translational modification of proteins found in eukaryotic and 
prokaryotic organisms (Weerapana and Imperiali, 2006). In eukaryotes, protein N-linked 
glycans are involved in many essential biological processes including the immune 
response, intracellular targeting, cell-cell recognition, protein folding and protein stability 
(Varki, 1993).  
The eukaryotic N-glycosylation pathway starts with the assembly of the 
Glc3Man9GlcNAc2 oligosaccharide precursor on a dolichol-PP carrier in an enzymatic 
multistep and well-ordered process known as the dolichol cycle (Burda and Aebi, 1999). 
This dolichol cycle takes place in two compartments: the cytosol and the endoplasmic 
reticulum (ER). It starts with the elongation of dolichol-P to Man5GlcNAc2-PP-dolichol 
on the cytosolic face of the ER membrane, while the elongation of Man5GlcNAc2-PP-
dolichol to the complete Glc3Man9GlcNAc2–PP-dolichol occurs in the ER lumen. For this 
reason, the Man5GlcNAc2-PP-dolichol intermediate has to be translocated across the ER 
membrane. In yeast, the ER membrane protein Rft1 was shown to facilitate the 
translocation of Man5GlcNAc2-PP-dolichol to the ER lumen in a bidirectional and ATP-
independent manner (Helenius et al., 2002). Once the fully assembled oligosaccharide 
precursor is synthesized, Glc3Man9GlcNAc2 is transferred onto selected asparagine 
residues of polypeptide chains by the oligosaccharyltransferase (OST) complex (Burda 
and Aebi, 1999).  
 
Congenital Disorders of Glycosylation (CDG) are a group of inherited human disorders 
characterized by deficient protein glycosylation. Up to now, 14 different CDG types 
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deficient in protein N-glycosylation site occupancy have been identified. Based on the  
serum sialotransferrin pattern, these N-glycosylation disorders can be classified into two 
subgroups: defects of oligosaccharide precursor assembly and transfer to proteins 
(formerly known as CDG-I) and defects of N-glycoprotein processing (formerly known 
as CDG-II) (Eklund and Freeze, 2006; Freeze, 2007; Jaeken and Matthijs, 2007; Leroy, 
2006). 
Recently, the first RFT1-deficient CDG patient was identified (Haeuptle et al., 2008). 
Haeuptle and co-workers described a young girl presenting with marked psychomotor 
retardation, hypotonia, seizures, hepatomegaly and coagulopathy. This patient was 
homozygous for the missense mutation c.199C>T (p.R67C) in the RFT1 protein and 
accumulated the Man5GlcNAc2-PP-dolichol intermediate on lipid-linked oligosaccharide 
(LLO) analysis. However, no Man5GlcNAc2 was transferred onto glycoproteins, which 
pointed to a deficient translocation of the accumulated LLO across the ER membrane.  
 
In the present study, we describe three additional RFT1-deficient patients including two 
novel pathogenic point mutations. While only one RFT1-deficient patient was known so 
far, the identification of these three additional patients allowed us to refine the clinical 
phenotype characteristic for RFT1 deficiency, designated as RFT1-CDG according to the 
novel nomenclature (Jaeken et al., 2008). 
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Materials and methods 
Cell culture 
Primary skin fibroblasts from healthy controls and patients were cultured at 37 °C under 
5% CO2 in DMEM/F12 (Life Technologies) supplemented with 10% fetal bovine serum 
(Clone III, HyClones). 
 
Mutation analysis 
Total RNA was isolated from 2 x 107 fibroblasts using the TRIzol LS reagent 
(Invitrogen) according to the manufacturer’s instructions. The human RFT1 cDNA was 
prepared and the protein coding region was amplified by PCR as described before 
(Haeuptle et al., 2008). The PCR products were sequenced (Synergene Biotech) after 
removal of the unincorporated nucleotides with QIAquick columns (QIAGEN). Carrier 
analysis in the parents and healthy siblings was performed on DNA extracted from blood. 
Primers were designed to amplify exons 3, 4 and 9 of the RFT1 gene, based on the 
genomic sequence (NM_052859). Primer sequences are available on request. These 
exons were amplified using standard PCR conditions, subsequently sequenced with the 
Big Dye Terminator Ready reaction cycle sequencing kit V3.1 (Applera) and analyzed on 
an ABI3100 Avant (Applera).  
 
Metabolic radiolabelling  
Fibroblasts (8 x 106 per labelling) were grown overnight in a 175 cm2 tissue culture flask. 
After 24 h, cells were pre-incubated in 0.5 mM glucose for 45 min and then pulse 
radiolabelled for 1 h with 150 µCi of 2-[3H]-mannose (16 Ci/mmol, Amersham 
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Biosciences). After metabolic labelling, the cells were scraped with 1.1 ml MeOH/H2O 
(8:3) followed by the addition of 1.2 ml CHCl3. Sequential extraction of oligosaccharide 
material was performed as previously described (Cacan and Verbert, 1997). 
 
Analysis of oligosaccharide material 
Glycoprotein fractions obtained at the end of the sequential extraction were digested 
overnight at room temperature with trypsin (1 mg/ml; Sigma) in 0.1 M ammonium 
bicarbonate buffer, pH 7.9. The resulting glycopeptides were treated with 0.5 U PNGase 
F (Roche) in 50 mM phosphate buffer, pH 7.2 for 4 h to release the oligosaccharides from 
the peptides. The oligosaccharides were desalted on Bio-Gel P2 columns and eluted with 
5% acetic acid. LLO fractions obtained after sequential extraction were subjected to mild 
acid treatment (0.1 M HCl in THF) for 2 h at 50 °C. Purification of the released 
oligosaccharides was performed as described above. 
The oligosaccharides were separated by HPLC on an amino derivated Asahipak NH2P-50 
column (250 mm x 4.6 mm; Asahi) applying a gradient of acetonitrile/H2O ranging from 
70:30 to 50:50 over 90 min at a flow rate of 1 ml/min. Oligosaccharides were identified 
on the basis of their retention times compared to standard glycans (Foulquier et al., 
2002). Elution of the radiolabelled oligosaccharides was monitored by continuous β-
counting with a flo-one β detector (Packard). 
 
Complementation of the LLO profile 
Lentiviruses containing RFT1 and EGFP cDNAs were prepared as previously described 
(Haeuptle et al., 2008). Briefly, 3 x 106 HEK293T cells were transfected with 20 µg 
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pLenti6-hRFT1 or pLenti6-EGFP and 36 µg of the packing plasmid mix (Invitrogen) by 
calcium-phosphate precipitation. Two days after transfection, the supernatants were 
collected and used to transduce the patient fibroblasts. After selection with 5 µg/ml 
blasticidin (Invitrogen), the cells were metabolically labelled with 2-[3H]-mannose and 
the extracted LLO were analysed by HPLC (Zufferey et al., 1995). 
 
Complementation of DNase 1 secretion 
Bovine DNase I cDNA was subcloned into the pSVK3 vector as previously reported 
(Nishikawa et al., 1997). Patients’ fibroblasts were transduced with an adenovirus 
expressing bovine DNase I (Eklund et al., 2005; Fujita et al., 2008). Two days post 
transduction, the cells were washed twice with PBS and incubated at 37 °C with 1 ml 
DMEM without methionine/cysteine, containing 10% dialysed fetal bovine serum, 10 
mM NH4Cl and 0.2 mCi [35S]-Met/Cys labelling mixture. After a labelling time of 4 h, 
the culture medium was harvested and DNase 1 was immunoprecipitated as previously 
described (Nishikawa and Mizuno, 2001). The immunoprecipitated samples were 
subjected to SDS-PAGE using a 13% acrylamide gel. After electrophoresis, the gels were 
rinsed with a mixture of 7% acetic acid and 10% methanol for 15 min and soaked in 
Amplify solution (Amersham Pharmacia Biotech) for 15 min. The gel was dried, 
autoradiography was carried out and the intensity of the bands corresponding to DNase I 
was quantified by scanning densitometery (using Quantity One software PDI). Band 
intensity was normalized against protein levels. 
 
 9 
Results 
Biochemical and molecular diagnosis 
Three patients with a type 1 pattern of serum sialotransferrins were further investigated. 
Subsequently, phosphomannomutase (CDG-Ia) and phosphomannose isomerase (CDG-
Ib) deficiencies were excluded on the basis of enzymatic activity measurements in the 
patients’ fibroblasts (data not shown).  
In order to identify a defect in the assembly of the oligosaccharide precursor within the 
dolichol cycle, structural analysis of the LLO was performed by HPLC after metabolic 
labelling. In healthy control fibroblasts, the LLO profile is characterized by the fully 
assembled oligosaccharide precursor Glc3Man9GlcNAc2-PP-dolichol. In contrast, an 
accumulation of Man5GlcNAc2-PP-dolichol in combination with only a minor amount of 
complete LLO was detected in all three patients (Figure 1, panels A, B, C and D). 
Additionally, protein-linked glycan structures were analyzed. In both, healthy control and 
patients, Man8GlcNAc2, Man9GlcNAc2 and Glc1Man9GlcNAc2 structures were obtained 
(Figure 1, panels E, F, G and H). Notably, no Man5GlcNAc2 structure could be detected 
on the patients’ glycoproteins.  
The accumulation of Man5GlcNAc2-PP-dolichol on LLO combined with normal protein-
linked glycans is typical for a defect in the translocation of Man5GlcNAc2-PP-dolichol to 
the ER lumen and was recently reported in a RFT1-deficient patient (Haeuptle et al., 
2008). To this end, mutation analysis of the RFT1 cDNA was performed in the present 
patients and all three carried RFT1 mutations. The first patient was homozygous for the 
earlier reported missense mutation (c.199C>T; p.R67C), while the parents were found to 
be heterozygous carriers of this mutation (Figure 2A) (Haeuptle et al., 2008). Two novel 
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point mutations were identified in two other patients. Sequencing of the second patient’s 
RFT1 cDNA revealed an A to G transition at nucleotide position 454, leading to the 
conversion of a lysine into a glutamic acid at position 152 on the protein level (Figure 
2B). Both parents as well as a healthy sibling were heterozygous for this mutation. In 
model eukaryotic organisms, the lysine at position 152 was mostly conserved and a 
conversion of a lysine into a glutamic acid was not observed (data not shown). The third 
patient was homozygous for a G to A transition at nucleotide position 892, causing a 
glutamic acid to lysine change at position 298 (Figure 2C). The mutated glutamic residue 
is strictly conserved among eukaryotes (data not shown). No material of the parents and 
siblings was available for carrier analysis.  
In addition, all converted amino acids were found in hydrophilic domains of the RFT1 
protein predicted to be oriented to the ER lumen (TMpred (Hofmann and Stoffel, 1993); 
TMHMM (Krogh et al., 2001)) (Figure 3). As previously reported, the p.R67C mutation 
is located in the first luminal loop of the RFT1 protein (Haeuptle et al., 2008). The 
p.K152E mutation was found in the second luminally oriented 25 amino acid long 
hydrophilic stretch and the p.E298K mutation was positioned in the largest luminal loop, 
bearing a potential N-glycosylation site at position p.N227 and ranging over 130 amino 
acids (Figure 3). 
 
Complementation of the LLO profile 
To demonstrate the pathogenicity of the two new missense mutations, wild-type RFT1 
cDNA was transduced into patients’ fibroblasts using a lentiviral construct to 
complement the Man5GlcNAc2-PP-dolichol accumulation. Healthy control and patients’ 
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fibroblasts were thus infected with recombinant lentiviruses expressing either the wild-
type RFT1 cDNA or EGFP as a negative control. Compared to EGFP expression in the 
patients’ fibroblasts, analysis after RFT1 expression revealed a normalization of the LLO 
profile characterized by decreased levels of Man5GlcNAc2-PP-dolichol and increased 
levels of the complete Glc3Man9GlcNAc2-PP-dolichol (Figure 4). EGFP expression in 
the patients’ fibroblasts did not affect the LLO profile, as expected.  
 
Complementation of DNase 1 secretion 
In another, alternative method to prove the pathogenicity of the two new mutations, 
secretion of recombinant, bovine DNase 1 was investigated in all three RFT1-deficient 
patients. A modified version of bovine DNase 1 has a single potential N-glycosylation 
site (p.N106) and is secreted when expressed in human fibroblasts (Nishikawa and 
Mizuno, 2001). However, upon expression in the fibroblasts of CDG patients, DNase 1 
secretion was strongly reduced (Eklund et al., 2005; Fujita et al., 2008). As shown in 
Figure 5 (lanes 3, 5 and 7), DNase 1 secretion was significantly reduced in all three 
RFT1-deficient patients. Transduction of the patient’s fibroblasts with lentiviruses coding 
for wild-type RFT1 restored the levels of DNase 1 secretion (Figure 5, lanes 4, 6 and 8), 
thus demonstrating the pathogenicity of the new mutations.  
 
Clinical phenotype 
To address the main clinical characteristics of RFT1 deficiency, the clinical phenotype of 
the three different patients was compared. Patient 1 was the first child of healthy, 
unrelated North Americans of Scottish-English origin and presented with respiratory 
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insufficiency, severe generalized epilepsy with intractable seizures, infantile spasms, 
microcephaly, failure to thrive, hypotonia, sensorineural deafness and decreased visual 
acuity. In addition, this patient showed severe mental retardation, with virtually no 
development. Dysmorphic features included micrognathia, short neck, small nose, 
drooping eyelids, valgus feet and adducted thumbs. This patient also had severe feeding 
problems requiring gastrostomy and died at the age of eight months. Brain MRI at early 
age did not reveal cerebral nor cerebellar atrophy. However, at autopsy, weight and 
gyral/sulcal pattern consistent with a degree of cerebral atrophy was reported (Table 1).  
The second patient was the second son of healthy, consanguineous Italian parents. During 
the first year of life, he presented with severe developmental delay, microcephaly, 
nystagmus, sensorineural deafness, relapsing aspiration pneumonia, a generalized 
hypotonia and inverted nipples. Additionally, this patient was frequently hospitalized 
because of drug-resistant epilepsy and feeding problems requiring gastrostomy. At the 
age of 4 years, CT scan of the brain revealed a stroke-like episode affecting the left 
frontal lobe, and the following year he started to suffer from recurrent deep venous 
thrombosis of the left leg. Clinical examination at the age of five years showed a severe 
mentally retarded child with microcephaly, spastic tetraparesis and kyphoscoliosis. Serial 
brain MRI examinations showed progressive cortical and subcortical atrophy with no 
cerebellar involvement and liver function has always been normal (Table 1). 
The third patient was the ninth child of healthy, consanguineous parents from Algerian 
origin. This family has two children presenting with the autosomal recessive disorder 
Hemophagocytic Lymphohistiocytosis. One child died at the age of three months, while 
the other is still alive due to bone marrow transplantation at the age of four months. In 
 13 
addition, one son died at the age of four days and presented with similar characteristics as 
his brother. Patient 3 presented with respiratory insufficiency, hypotonia, body spasm, 
failure to thrive, epilepsy, bilateral glaucoma and sensorineural deafness. Dysmophic 
features included slightly inverted nipples, infiltrated ears, short neck, retrognathism, 
glossoptosis, adducted thumbs and valgus feet. Brain MRI did not show cerebral or 
cerebellar atrophy. This patient also had feeding problems and chronic infections of the 
respiratory tract. In addition, he showed severe mental retardation with the absence of 
visual contact and liver function was normal (Table 1).  
 
Discussion 
Based on the analysis of LLO and protein-linked glycan profiles in fibroblasts, three 
potential RFT1-deficient patients were identified. All three patients showed an 
accumulation of the LLO Man5GlcNAc2-PP-dolichol, while no Man5GlcNAc2 was 
detected on glycoproteins. Mutation analysis of the RFT1 gene revealed that one patient 
was homozygous for the earlier reported missense mutation (c.199C>T, p.R67C). This is 
the second report of the p.R67C mutation in a patient of British origin (Imtiaz et al., 
2000), which could point to a founder effect of the p.R67C mutation. The other patients 
were homozygous for the new missense mutations c.454A>G (p.E152K) and c.892G>A 
(p.K298E). The pathogenic character of these novel mutations was demonstrated by the 
complementation of the abnormal LLO profile and reduced DNase 1 secretion upon 
expression of wild-type RFT1 in the patients’ fibroblasts. 
All three RFT1 mutations identified so far are located in one of the hydrophilic loops 
predicted to be within the ER lumen. It can be assumed that these regions are of major 
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importance for the translocation of Man5GlcNAc2-PP-dolichol in the ER lumen or for the 
maintenance of Man5GlcNAc2-PP-dolichol on the luminal side. Further structural 
analysis will be required to confirm the predicted orientation of the RFT1 protein. 
Determination of the occupancy of the putative N-glycosylation site at position p.N227 
(Figure 3) would certainly contribute to establish the topology of the RFT1 protein.  
In yeast, the Rft1 protein was genetically identified as a protein mediating the 
translocation of LLO across the ER membrane (Helenius et al., 2002). However, recent 
evidence suggests that the RFT1 protein would not be the flippase enzyme itself, but 
would play a critical accessory role in translocating Man5GlcNAc2-PP-dolichol to the ER 
lumen (Frank et al., 2008; Sanyal et al., 2008). Anyhow, the identification of three 
additional RFT1-deficient patients clearly underscores the major importance of RFT1 in 
this translocation event.  
Finally, the identification of three additional patients allowed us to refine the clinical 
phenotype characteristic for RFT1 deficiency. All four known RFT1-deficient patients 
showed very similar characteristics including severe mental retardation, hypotonia, 
epilepsy, myoclonic jerks, decreased visual acuity, sensorineural deafness and feeding 
problems (Table 1). In comparison to other CDG defects, RFT1 deficiency is thus mainly 
a neurological disorder. A striking clinical feature is the presence of sensorineural 
deafness in all four RFT1-deficient patients (Imtiaz et al., 2000). Deafness has been 
reported in only a few other CDG patients (Imtiaz et al., 2000; Kranz et al., 2007; 
Hutchesson et al., 1995). More RFT1-deficient patients have to be studied in order to 
know whether this is a consistent feature of RFT1-CDG. 
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Tables 
 Patient 1 Patient 2 Patient 3 Patient KS 
Gender female male male female 
Origin Scottish Italian Algerian English 
Vital status died 8 m alive 5.5 y alive 2.2y died 4.3 y 
Consanguinity - + + - 
     
Feeding problems + + + + 
Failure to thrive + + + + 
Severe mental retardation + + + + 
Microcephaly + + - na 
Hypotonia + + + + 
Epilepsy + + + + 
Decreased visual acuity + + + + 
Sensorineural deafness + + + + 
Myoclonic jerks  + + + + 
Respiratory insufficiency + - + na 
Pulmonary infections - + + + 
Coagulopathy na + na + 
     
Dysmophic features: micrognathia + - + na 
 short neck + - + na 
 valgus feet + + + na 
 
adducted 
thumbs + na + - 
 kyphoscoliosis na + na + 
 
inverted 
nipples - + + + 
Brain MRI: 
cerebral 
atrophy   -* + - + 
 
cerebellar 
atrophy - - - + 
 
Table 1: Clinical phenotype of the three new RFT1-deficient patients compared to the 
phenotype of the originally reported case (KS) (Clayton and Grunewald, 2009; Haeuptle 
et al., 2008; Imtiaz et al., 2000). Symbols: na: not available; *: cerebral atrophy reported 
at autopsy. 
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Figure Legends 
Figure 1: (A-D) HPLC analysis of the LLO in control and patients’ fibroblasts revealing 
the accumulation of Man5GlcNAc2-PP-dolichol in the case of CDG. (E-H) Protein N-
linked oligosaccharides of control and patients were separated by HPLC, demonstrating 
that no aberrant glycan structures were detected in the patients. The retention times of the 
standard oligosaccharides Glc3Man9GlcNAc2-PP-dolichol (G3M9) and Man1-9GlcNAc2-
PP-dolichol (M1-9) are marked above the HPLC profiles. 
 
Figure 2: Sequence alignment of the RFT1 cDNA fragments in control and patients. (A) 
Patient 1 is homozygous for the earlier reported missense mutation c.199C>T (p.R67C). 
(B) In patient 2, the homozygous A to G transition at nucleotide position c.454 was 
detected, leading to a conversion of a lysine into a glutamic acid at position p.152. (C) 
Analysis of the RFT1 cDNA in patient 3 revealed a homozygous G to A transition at 
nucleotide position c.892, causing a glutamic acid to lysine change at protein position 
p.298. 
 
Figure 3: Schematic representation of the identified missense mutations in the predicted 
topology of the RFT1 protein. All three mutations were found in the predicted luminal 
loops of the protein. The orientation of the model was supported by the favoured position 
of the 11 transmembrane domains and the localization of a potential N-glycosylation site 
(p.N227) (TMpred (Hofmann and Stoffel, 1993); TMHMM (Krogh et al., 2001)). 
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Figure 4: Complementation of the Man5GlcNAc2-PP-dolichol accumulation. Fibroblasts 
of patient 2 (A) and patient 3 (C) express wild-type RFT1 cDNA, thereby leading to a 
decreased accumulation of Man5GlcNAc2-PP-dolichol. Lentiviral mediated expression of 
EGFP in the fibroblasts of patient 2 (B) and patient 3 (D) showed no effect. The retention 
times of the standard oligosaccharides Glc3Man9GlcNAc2-PP-dolichol (G3M9) and Man1-
9GlcNAc2-PP-dolichol (M1-9) are marked above the HPLC profiles. 
 
Figure 5: Rescue of DNase 1 secretion in the patients’ fibroblasts. Secretion of DNase 1 
is reduced in the fibroblasts of CDG patients (lanes 3, 5 and 7). Expression of wild-type 
RFT1 cDNA (lanes 4, 6 and 8) restored the secretion of DNase 1 to a level equal to 
controls (lanes 1 and 2). Symbols: o = non-glycosylated DNase 1; 1 = singly glycosylated 
DNase 1. 
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